Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302637 · ClinicalTrials.gov registry record
Oral Microbiome and Pancreatic Cancer
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 732
- Enrollment target
NCT03302637: Completed study, sponsored by NYU Langone Health.
NCT03302637 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 732 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03302637 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 732 participants
- Enrollment target
Study Summary
This is a prospective population based study to examine the relationship of oral and pancreatic microbiome, and their functions, to pancreatic cancer risk. The identification of specific oral bacteria and their functional relationship to pancreatic cancer will advance scientific knowledge on the etiology of pancreatic cancer. This could provide a new microbially-based research paradigm, possibly leading to new drug targets for this disease. Second, the oral bacteria may serve as a readily accessible, non-invasive biomarker for subsequent pancreatic cancer risk, which help to identify people at high risk of this disease. Finally, the identified oral bacteria may lead to microbial prophylactic preventions, with antibiotic therapy aimed at eradicating the specific species associated with increased cancer risk or, alternatively, combined with probiotics to introduce species that are associated with a decreased cancer risk. Thus, the study outcomes will lead to actionable means for pancreatic cancer prevention.
Primary Outcome
For the taxa present at both sites, correlation between the abundance of taxa will be examined between the two sites. To adjust for confounders, multivariate linear regression will be used with abundance of oral taxa (exposure) and that of pancreas taxa (outcome).
Interventions
- OTHER 16S rRNA gene sequencing assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 1992-12-01 |
| Est. Completion | 2010-12-01 |
What the finished NCT03302637 record still lists
NCT03302637 is an observational study that tracks outcomes without assigning an intervention. The registered 732 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which 16S rRNA gene sequencing assay is the first listed.
NCT03302637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03302637 about?
NCT03302637 is a clinical study titled "Oral Microbiome and Pancreatic Cancer". This is a prospective population based study to examine the relationship of oral and pancreatic microbiome, and their functions, to pancreatic cancer risk. The identification of specific oral bacteria and their functional relationship to pancreatic cancer will advance scientific knowledge on the et...
What is the current status of trial NCT03302637?
This trial is currently completed. The enrollment target is 732 participants. The study started on 1992-12-01. Estimated completion is 2010-12-01.
What interventions are being tested in trial NCT03302637?
The interventions under investigation include: 16S rRNA gene sequencing assay (OTHER).
Who is sponsoring clinical trial NCT03302637?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI